HRP20171133T1 - Psma-vezujući agensi i njihove uporabe - Google Patents

Psma-vezujući agensi i njihove uporabe Download PDF

Info

Publication number
HRP20171133T1
HRP20171133T1 HRP20171133TT HRP20171133T HRP20171133T1 HR P20171133 T1 HRP20171133 T1 HR P20171133T1 HR P20171133T T HRP20171133T T HR P20171133TT HR P20171133 T HRP20171133 T HR P20171133T HR P20171133 T1 HRP20171133 T1 HR P20171133T1
Authority
HR
Croatia
Prior art keywords
radioisotope
substance according
iodine
fluorine
bromine
Prior art date
Application number
HRP20171133TT
Other languages
English (en)
Croatian (hr)
Inventor
Martin Gilbert Pomper
Ronnie Charles Mease
Ying Chen
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of HRP20171133T1 publication Critical patent/HRP20171133T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nuclear Medicine (AREA)
HRP20171133TT 2008-08-01 2009-07-31 Psma-vezujući agensi i njihove uporabe HRP20171133T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8546208P 2008-08-01 2008-08-01
US11179108P 2008-11-06 2008-11-06
EP09803670.0A EP2318366B1 (en) 2008-08-01 2009-07-31 Psma-binding agents and uses thereof
PCT/US2009/052456 WO2010014933A2 (en) 2008-08-01 2009-07-31 Psma-binding agents and uses thereof

Publications (1)

Publication Number Publication Date
HRP20171133T1 true HRP20171133T1 (hr) 2017-10-20

Family

ID=41610978

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20220742TT HRP20220742T1 (hr) 2008-08-01 2009-07-31 Sredstva koja se vežu na psma i njihova upotreba
HRP20171133TT HRP20171133T1 (hr) 2008-08-01 2009-07-31 Psma-vezujući agensi i njihove uporabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20220742TT HRP20220742T1 (hr) 2008-08-01 2009-07-31 Sredstva koja se vežu na psma i njihova upotreba

Country Status (24)

Country Link
US (7) US8778305B2 (enExample)
EP (3) EP3222615B1 (enExample)
JP (6) JP5588441B2 (enExample)
KR (1) KR101664855B1 (enExample)
CN (3) CN113563262A (enExample)
AU (1) AU2009276423B2 (enExample)
CA (2) CA2987744C (enExample)
CY (3) CY1119367T1 (enExample)
DK (2) DK2318366T3 (enExample)
ES (2) ES2914593T3 (enExample)
FI (1) FIC20230033I1 (enExample)
FR (1) FR23C1044I2 (enExample)
HK (1) HK1247197A1 (enExample)
HR (2) HRP20220742T1 (enExample)
HU (3) HUE034027T2 (enExample)
LT (3) LT3222615T (enExample)
NL (1) NL301250I2 (enExample)
NO (1) NO2024006I1 (enExample)
PL (2) PL2318366T3 (enExample)
PT (2) PT2318366T (enExample)
RU (1) RU2494096C2 (enExample)
SI (2) SI2318366T1 (enExample)
SM (1) SMT201700371T1 (enExample)
WO (1) WO2010014933A2 (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2009070302A1 (en) * 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
US8855387B2 (en) 2007-12-28 2014-10-07 Exini Diagnostics Ab System for detecting bone cancer metastases
PL2318366T3 (pl) * 2008-08-01 2017-10-31 Univ Johns Hopkins Środki wiążące PSMA i ich zastosowania
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
ES2941937T3 (es) 2011-11-30 2023-05-26 Univ Johns Hopkins Compuesto dirigido a PSMA y sus usos
US20140065070A1 (en) * 2012-08-28 2014-03-06 Mcmaster University Methods of preparing triazole-containing radioiodinated compounds
EP3858341A1 (en) * 2012-11-15 2021-08-04 Endocyte, Inc. Psma ligand-containing conjugates for the treatment of prostate cancer
DK2970345T3 (da) * 2013-03-15 2019-08-26 Cancer Targeted Tech Llc 18f-mærkede psma-targeterede pet-kontrastmidler
WO2015057692A1 (en) 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
JP6292568B2 (ja) * 2013-11-06 2018-03-14 国立大学法人京都大学 ウレア誘導体化合物、これを含有する放射性医薬
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US9713649B2 (en) 2014-01-24 2017-07-25 The Cleveland Clinic Foundation PSMA-targeting imaging agents
US10556916B2 (en) 2014-04-01 2020-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography
EP2993171A1 (en) * 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
PL3183236T3 (pl) * 2014-08-24 2022-07-18 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3011976A1 (en) * 2014-10-20 2016-04-27 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
US10736974B2 (en) 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US20180338910A1 (en) * 2015-01-09 2018-11-29 The Johns Hopkins University Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors
US10869940B2 (en) 2015-06-12 2020-12-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted photoacoustic compounds, formulations, and uses thereof
WO2017029399A1 (en) * 2015-08-20 2017-02-23 Universität Zu Köln Pain tracking by pet-imaging (pain-trap)
KR102233726B1 (ko) 2015-09-30 2021-03-31 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
US20200231614A1 (en) * 2015-10-22 2020-07-23 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
KR101639599B1 (ko) 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
WO2017117687A1 (en) 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen
PL3481804T3 (pl) * 2016-06-10 2025-04-07 The Johns Hopkins University ULEPSZONA SYNTEZA ZNAKOWANEGO RADIOAKTYWNIE INHIBITORA [18F]DCFPyL ANTYGENU BŁONOWEGO SPECYFICZNEGO DLA GRUCZOŁU KROKOWEGO (PSMA)
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
CN109843339B (zh) * 2016-06-23 2023-07-07 康奈尔大学 影响肿瘤杀伤的双重靶向构建体
AU2017348111B2 (en) 2016-10-27 2023-04-06 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
WO2018090974A1 (zh) * 2016-11-17 2018-05-24 思路迪（北京）医药科技有限公司 一种具有抗癌作用的化合物及其制备方法和应用
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung
CA3058663A1 (en) 2017-04-05 2018-10-11 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
AU2018250336B2 (en) * 2017-04-07 2025-02-20 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
US11491247B2 (en) 2017-05-02 2022-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2018236115A1 (ko) 2017-06-19 2018-12-27 (주)퓨쳐켐 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
JP6913968B2 (ja) 2017-06-19 2021-08-04 フューチャーケム カンパニー リミテッドＦｕｔｕｒｅｃｈｅｍ Ｃｏ．，Ｌｔｄ． 前立腺がんの診断のための１８ｆ標識化合物およびその使用
WO2019083990A2 (en) * 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)
PT4008359T (pt) * 2017-12-11 2024-10-25 Univ Muenchen Tech Ligandos psma para imagiologia e endorradioterapia
US10973486B2 (en) 2018-01-08 2021-04-13 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
EP4586195A3 (en) 2018-01-08 2025-10-22 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
IL276528B2 (en) 2018-02-06 2024-11-01 Univ Johns Hopkins PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
CN109160898B (zh) * 2018-05-16 2021-06-04 上海如絮生物科技有限公司 一种亲水性吡啶类化合物中间体及其制备方法
CN109160896B (zh) * 2018-05-16 2021-06-25 上海如絮生物科技有限公司 一种亲水性吡啶类化合物中间体及其制备方法
CN109160899B (zh) * 2018-05-16 2021-06-04 上海如絮生物科技有限公司 一种亲水性吡啶类化合物、中间体、其制备方法及应用
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
JP2022508692A (ja) 2018-10-11 2022-01-19 プロゲニクス ファーマシューティカルズ，インコーポレーテッド 転移性前立腺がんを処置するための併用療法
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
KR102403970B1 (ko) 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
EP3909014B1 (en) 2019-01-07 2025-04-02 Exini Diagnostics AB Systems and methods for platform agnostic whole body image segmentation
PL239934B1 (pl) * 2019-04-12 2022-01-31 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
CN113748443B (zh) 2019-04-24 2025-09-09 普罗热尼奇制药公司 用于交互式调整核医学图像中的强度窗口设定的系统和方法
TWI872062B (zh) 2019-04-24 2025-02-11 美商普吉尼製藥公司 用於偵測轉移之骨掃描影像之自動及互動式分析系統、裝置及方法
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
JP7618599B2 (ja) 2019-06-21 2025-01-21 プロビンシャル・ヘルス・サービシーズ・オーソリティ 前立腺特異的膜抗原を標的とする放射性標識化合物
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
EP4021455A4 (en) * 2019-08-30 2023-10-04 Memorial Sloan Kettering Cancer Center NOVEL THERANOSTIC AGENT FOR PSMA-POSITIVE CANCERS
US11564621B2 (en) 2019-09-27 2023-01-31 Progenies Pharmacenticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11544407B1 (en) 2019-09-27 2023-01-03 Progenics Pharmaceuticals, Inc. Systems and methods for secure cloud-based medical image upload and processing
KR102269315B1 (ko) 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
US11321844B2 (en) 2020-04-23 2022-05-03 Exini Diagnostics Ab Systems and methods for deep-learning-based segmentation of composite images
US11386988B2 (en) 2020-04-23 2022-07-12 Exini Diagnostics Ab Systems and methods for deep-learning-based segmentation of composite images
CN111548305B (zh) * 2020-05-12 2021-08-31 北京师范大学 一种可用于靶向psma的喹啉类化合物及其制备方法
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
JP2023532761A (ja) 2020-07-06 2023-07-31 エクシーニ ディアグノスティクス アーべー 病変の検出および特性評価のための人工知能ベースの画像分析のためのシステムならびに方法
WO2022101352A1 (en) 2020-11-12 2022-05-19 Abx Advanced Biochemical Compounds Gmbh Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
US20240293586A1 (en) 2021-07-30 2024-09-05 Osaka University Radiolabeled compound and use thereof
US20230115732A1 (en) 2021-10-08 2023-04-13 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases
WO2023086833A1 (en) 2021-11-09 2023-05-19 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
TW202414429A (zh) 2022-06-08 2024-04-01 瑞典商艾西尼診斷公司 評估疾病負荷及進展之系統及方法
AU2024208501A1 (en) 2023-01-10 2025-07-24 Sun Pharma Advanced Research Company Limited Ligand-drug conjugates
US20240285248A1 (en) 2023-02-13 2024-08-29 Progenics Pharmaceuticals, Inc. Systems and methods for predicting biochemical progression free survival in prostate cancer patients
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
US20240354940A1 (en) 2023-04-07 2024-10-24 Progenics Pharmaceuticals, Inc. Systems and methods for facilitating lesion inspection and analysis
WO2025072177A1 (en) 2023-09-25 2025-04-03 Progenics Pharmaceuticals, Inc. Systems and methods for automated cancer staging and risk prediction
WO2025090594A1 (en) * 2023-10-25 2025-05-01 The Johns Hopkins University Deep transfer learning for fully automated tumor quantification and prognosis of cancer on pet/ct
DE102023133281B8 (de) * 2023-11-28 2025-07-24 Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien Gmbh Radiotracer und Präkursoren für diese Radiotracer sowie Verwendung dieser Radiotracer als Diagnostika und Therapeutika
CN117670883B (zh) * 2024-01-31 2024-05-07 中国医学科学院北京协和医院 一种鉴别高低级别膀胱癌的方法、设备和系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2233269C2 (ru) * 1998-11-02 2004-07-27 Авентис Фарма Лимитед Замещенные анилиды, фармацевтическая композиция и способ лечения
JP3750494B2 (ja) 1999-08-31 2006-03-01 松下電器産業株式会社 半導体装置
WO2006093991A1 (en) * 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
PL3699162T3 (pl) 2006-11-08 2022-10-31 Molecular Insight Pharmaceuticals, Inc. Heterodimery kwasu glutaminowego
EP2921482B1 (en) * 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
CA2891005A1 (en) * 2007-09-28 2008-10-09 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles
PL2318366T3 (pl) 2008-08-01 2017-10-31 Univ Johns Hopkins Środki wiążące PSMA i ich zastosowania
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
PL3481804T3 (pl) * 2016-06-10 2025-04-07 The Johns Hopkins University ULEPSZONA SYNTEZA ZNAKOWANEGO RADIOAKTYWNIE INHIBITORA [18F]DCFPyL ANTYGENU BŁONOWEGO SPECYFICZNEGO DLA GRUCZOŁU KROKOWEGO (PSMA)

Also Published As

Publication number Publication date
ES2914593T3 (es) 2022-06-14
CN107382846B (zh) 2021-07-06
US10500292B2 (en) 2019-12-10
HUS2300039I1 (hu) 2023-12-28
US20180236110A1 (en) 2018-08-23
JP2021095407A (ja) 2021-06-24
FIC20230033I1 (fi) 2023-11-02
HUE034027T2 (en) 2018-01-29
NL301250I2 (nl) 2023-11-23
US9226981B2 (en) 2016-01-05
FR23C1044I1 (fr) 2023-12-29
HK1247197A1 (zh) 2018-09-21
US8778305B2 (en) 2014-07-15
JP2019055973A (ja) 2019-04-11
EP2318366A2 (en) 2011-05-11
RU2494096C2 (ru) 2013-09-27
LTPA2023534I1 (enExample) 2023-12-11
EP2318366B1 (en) 2017-05-03
CN113563262A (zh) 2021-10-29
CA2987744A1 (en) 2010-02-04
WO2010014933A3 (en) 2010-05-20
SI2318366T1 (sl) 2017-10-30
JP5588441B2 (ja) 2014-09-10
SI3222615T1 (sl) 2022-11-30
PT3222615T (pt) 2022-06-20
JP6030724B2 (ja) 2016-11-24
LT3222615T (lt) 2022-08-25
KR20110038725A (ko) 2011-04-14
CN102171187A (zh) 2011-08-31
DK2318366T3 (en) 2017-08-21
US20220088229A1 (en) 2022-03-24
PL3222615T3 (pl) 2022-09-26
ES2634894T3 (es) 2017-09-29
US9861713B2 (en) 2018-01-09
JP5806765B2 (ja) 2015-11-10
DK3222615T3 (da) 2022-06-20
JP2016053025A (ja) 2016-04-14
JP6524046B2 (ja) 2019-06-05
CN102171187B (zh) 2017-07-28
HRP20220742T1 (hr) 2022-10-28
HUE059436T2 (hu) 2022-11-28
US20140369931A1 (en) 2014-12-18
US12070513B2 (en) 2024-08-27
EP4089074A1 (en) 2022-11-16
EP3222615A1 (en) 2017-09-27
JP7219497B2 (ja) 2023-02-08
JP2017048204A (ja) 2017-03-09
EP3222615B1 (en) 2022-05-04
PT2318366T (pt) 2017-08-02
CA2732632C (en) 2018-01-09
KR101664855B1 (ko) 2016-10-11
LTC2318366I2 (enExample) 2025-08-25
SMT201700371T1 (it) 2017-09-07
AU2009276423A1 (en) 2010-02-04
CN107382846A (zh) 2017-11-24
EP2318366A4 (en) 2011-12-14
CY2023024I1 (el) 2024-02-16
CY1125468T1 (el) 2025-05-09
CY1119367T1 (el) 2018-02-14
WO2010014933A2 (en) 2010-02-04
LT2318366T (lt) 2017-10-25
CA2987744C (en) 2022-11-15
US20110142760A1 (en) 2011-06-16
FR23C1044I2 (fr) 2024-08-23
CA2732632A1 (en) 2010-02-04
PL2318366T3 (pl) 2017-10-31
JP2015007058A (ja) 2015-01-15
JP7277113B2 (ja) 2023-05-18
AU2009276423B2 (en) 2014-10-30
NO2024006I1 (no) 2024-02-01
US20200282083A1 (en) 2020-09-10
JP2011529919A (ja) 2011-12-15
CY2023024I2 (el) 2024-12-13
US20160114060A1 (en) 2016-04-28
US20250177578A1 (en) 2025-06-05
RU2011107752A (ru) 2012-09-10

Similar Documents

Publication Publication Date Title
HRP20171133T1 (hr) Psma-vezujući agensi i njihove uporabe
JP2011529919A5 (enExample)
ES2877572T3 (es) Agentes de alta afinidad dirigidos a antígenos de membrana específicos de próstata para la endorradioterapia del cáncer de próstata
JP7503495B2 (ja) がん放射線治療法のための、ｐｓｍａをターゲットとした放射性ハロゲン化した尿素‐ポリアミノカルボン酸塩
US20240140971A1 (en) Psma targeted radiohalogenated ureas for cancer radiotherapy
ES2743482T3 (es) Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia
ES2997266T3 (en) Psma ligands for imaging and endoradiotherapy
NO20076349L (no) Stereoselektiv syntese av aminosyreanaloger for tumorbilleddannelse
JP2005525345A5 (enExample)
AR059767A1 (es) Profarmacos de analogos de cc-1065 y sus conjugados, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende y el uso de estos para la fabricacion de un medicamento para el tratamiento del cancer.
HRP20240952T1 (hr) Spojevi koji ciljaju psma i njihova uporaba
PE20110226A1 (es) Daa-piridina como ligando del receptor periferico de benzodiazepina
ES2552684T3 (es) Nuevos compuestos de imidazolidina como moduladores del receptor de andrógenos
NZ544583A (en) Bicyclic peptide imaging agents for in vivo diagnosis or imaging of a disease or condition associated with angiogenesis
SI2079486T1 (en) Effective synthesis of chelators for nuclear imaging and radiotherapy: composition and use
AR071054A1 (es) Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa.
WO2016065145A2 (en) Psma targeted reversed carbamates and methods of use thereof
AR065280A1 (es) Agentes antiparasitarios
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MY147347A (en) Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
JP2010516679A (ja) 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
JP2012520271A5 (enExample)
ES2654528T3 (es) Procedimiento de preparación de un derivado de purina marcado, dicho derivado y sus usos
AR075079A1 (es) Compuestos que se unen a las placas amiloides para obtener imagenes de las mismas, su uso, composicion, kit y metodo de tratamiento o prevencion.